Public Service Enterprise Group

PEG

Market cap $40.5B

Overview Fund Activity

81.19 USD

+0.76

0.94%

At close Updated Sep 18, 4:00 PM EDT

Pre-market

After hours

81.19

0.00

0%

1 day

0.94%

5 days

-0.82%

1 month

-3.48%

3 months

-1.11%

6 months

-1.19%

Year to date

-4.59%

1 year

-3.62%

5 years

58.17%

10 years

101.26%

About: Public Service Enterprise Group is the holding company for a regulated utility (PSE&G) and PSEG Power, which owns all or a share of three nuclear plans and clean energy projects. PSE&G provides regulated gas and electricity delivery services in New Jersey to a combined 4.3 million customers. Public Service Enterprise Group also operates the Long Island Power Authority system. In 2022, the company sold its gas and oil power plants in the mid-Atlantic, New York, and the Northeast.

Employees: 26,094

Utilities Electric Utilities

0

Funds holding %

of 7,463 funds

0

Analysts bullish %

of 4 analysts

Fund manager confidence

Based on 2025 Q2 regulatory disclosures by fund managers ($100M+ AUM)

264% more call options, than puts

Call options by funds: $162M | Put options by funds: $44.4M

67% more funds holding in top 10

Funds holding in top 10: 6 [Q1] → 10 (+4) [Q2]

13% more repeat investments, than reductions

Existing positions increased: 459 | Existing positions reduced: 406

1.26% more ownership

Funds ownership: 73.87% [Q1] → 75.13% (+1.26%) [Q2]

4% more capital invested

Capital invested by funds: $30.3B [Q1] → $31.5B (+$1.23B) [Q2]

3% less first-time investments, than exits

New positions opened: 112 | Existing positions closed: 115

2% less funds holding

Funds holding: 1,217 [Q1] → 1,193 (-24) [Q2]

See Fund Rankings

Research analyst outlook

4 Wall Street Analysts provided 1 year price targets over the past 3 months

Low target

$82

1% upside

Avg. target

$94

15% upside

High target

$103

27% upside

4 analyst ratings

2 positive

50%

2 neutral

50%

0 negative

0%

BMO Capital James Thalacker	$89	Market Perform Maintained	6 Aug 2025
UBS William Appicelli	$103	Buy Maintained	25 Jul 2025
Barclays Nicholas Campanella	$82	Equal-Weight Maintained	10 Jul 2025
Morgan Stanley David Arcaro	$100	Overweight Maintained	18 Jun 2025

See Analyst Rankings

Financial journalist opinion

Based on 5 articles about PEG published over the past 30 days

Zacks Investment Research

After Plunging 8.9% in 4 Weeks, Here's Why the Trend Might Reverse for PSEG (PEG)

The heavy selling pressure might have exhausted for PSEG (PEG) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal.

After Plunging 8.9% in 4 Weeks, Here's Why the Trend Might Reverse for PSEG (PEG)

Correction: Pharma Equity Group's subsidiary, Reponex Pharmaceuticals A/S, receives regulatory approval to initiate pivotal clinical trial with RNX-011 for life-threatening peritonitis

Pharma Equity Group's subsidiary, Reponex Pharmaceuticals A/S, receives regulatory approval to initiate pivotal clinical trial with RNX-011 for life-threatening peritonitis This company announcement replaces company announcement no. 10 published on 1 September 2025.

Correction: Pharma Equity Group's subsidiary, Reponex Pharmaceuticals A/S, receives regulatory approval to initiate pivotal clinical trial with RNX-011 for life-threatening peritonitis

Pharma Equity Group's subsidiary, Reponex Pharmaceuticals A/S, receives regulatory approval to initiate pivotal clinical trial with RNX-011 for life-threatening peritonitis

Pharma Equity Group's subsidiary, Reponex Pharmaceuticals A/S, receives regulatory approval to initiate pivotal clinical trial with RNX-011 for life-threatening peritonitis Copenhagen, September 01, 2025 Company Announcement No. 10 Reponex Pharmaceuticals A/S (Reponex), a subsidiary of Pharma Equity Group A/S (NASDAQ: PEG), today announced that it has received regulatory approval to initiate a pivotal Phase 2 clinical trial with its drug candidate RNX-011.

Pharma Equity Group's subsidiary, Reponex Pharmaceuticals A/S, receives regulatory approval to initiate pivotal clinical trial with RNX-011 for life-threatening peritonitis

Zacks Investment Research

VST vs. PEG: Which Utility Stock Can Provide Better Return Long-Term?

Vistra and Public Service Enterprise Group highlight differing advantages in growth, dividends and valuation, giving investors distinct long-term options.

VST vs. PEG: Which Utility Stock Can Provide Better Return Long-Term?

Public Service Enterprise: Long-Term Earnings Outlook Remains Very Positive

I maintain my strong buy rating on PEG, driven by surging data center demand and a robust 2Q25 earnings beat. PEG's large-load inquiry pipeline soared to 9.4 GW, with ~90% tied to data centers, underscoring a powerful multi-year growth runway. Higher PJM auction clearing prices and nuclear fleet optimization initiatives significantly boost PEG's earnings visibility and de-risk future cash flows.

Public Service Enterprise: Long-Term Earnings Outlook Remains Very Positive

Three Stocks Morgan Stanley Recommends for Playing the ‘Nuclear Renaissance'

The world is having a “nuclear renaissance,” according to Morgan Stanley, and the opportunity for investors is ample.

Three Stocks Morgan Stanley Recommends for Playing the ‘Nuclear Renaissance'

The Motley Fool

Public Service (PEG) Q2 EPS Jumps 22%

Public Service (PEG) Q2 EPS Jumps 22%

Public Service (PEG) Q2 EPS Jumps 22%

Public Service Enterprise Group Incorporated (PEG) Q2 2025 Earnings Call Transcript

Public Service Enterprise Group Incorporated (NYSE:PEG ) Q2 2025 Earnings Conference Call August 5, 2025 11:00 AM ET Company Participants Carlotta N. Chan - Vice President of Investor Relations Daniel J.

Public Service Enterprise Group Incorporated (PEG) Q2 2025 Earnings Call Transcript

Zacks Investment Research

Public Service Enterprise Q2 Earnings Beat Estimates, Revenues Increase Y/Y

PEG Q2 earnings and revenues outpace estimates, driven by strong gas sales and solid performance across segments.

Public Service Enterprise Q2 Earnings Beat Estimates, Revenues Increase Y/Y

Zacks Investment Research

Here's What Key Metrics Tell Us About PSEG (PEG) Q2 Earnings

Although the revenue and EPS for PSEG (PEG) give a sense of how its business performed in the quarter ended June 2025, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.

Here's What Key Metrics Tell Us About PSEG (PEG) Q2 Earnings

See News Rankings

Charts implemented using Lightweight Charts™